Objective: Knowledge of one's gene status for adult onset conditions provides opportunity to make advance end-of-life (EOL) plans. The purposes of these analyses were to (1) determine the prevalence of EOL plans, including advance directives (ADs) among persons across 3 stages of Huntington disease (HD) and (2) examine factors associated with having ADs in this sample. Methods: Data are from 503 participants in the HD Quality of Life study. Participants completed an online health-related qualityof-life survey that included questions regarding EOL planning and self-reported HD symptoms. Frequencies were calculated for EOL planning by the HD stage. Bivariate analysis and logistic regression were used to identify variables associated with having ADs. Results: A total of 38.2% of participants stated they had ADs and fewer than half had other EOL plans. Being older, increased HD stage, more years of education, lower anxiety, more swallowing symptoms, and higher meaning and purpose were associated with having ADs. Conclusion: The prevalence of ADs in our sample is comparable to the general US population, but surprisingly low, considering the severity and long disease course of HD. Practice Implications: Health-care providers should develop specific interventions early in the disease process to increase ADs in this population.
Introduction
Huntington disease (HD) is a devastating neurodegenerative disease for which there is palliative treatment, but no cure. The disease is caused by an autosomal dominant trinucleotide cytosine-adenine-guanine (CAG) repeat expansion on the HTT gene. Symptoms typically begin in the middle age and include progressive decline in cognitive, behavioral, motor, and day-today functioning 1 that significantly impact health-related quality of life (HRQOL). 2, 3 Progression to dementia is inexorable; death occurs approximately 17 to 20 years following motor diagnosis. 1 Presymptomatic genetic testing has been available since the discovery of the HTT gene mutation in 1993. 4 If a patient does not undergo presymptomatic genetic testing, diagnoses are made based on consistent family history with typical motor signs (eg, chorea) or confirmation by genetic testing. 5 One of the benefits of knowing one's gene status for an adult onset disease, especially one that involves dementia, is the ability to make advance end-of-life (EOL) decisions while one still has the cognitive capacity. 6 Advance directives (ADs), including living wills, healthcare powers of attorney, or health-care directives, are legal documents that state an individual's preferences for medical treatment and to appoint a surrogate to make decisions on their behalf if they become incapacitated. 7 Advance directives are effective in decreasing unwanted hospitalization and unwanted life-sustaining treatment, and increasing the use of palliative and hospice care. 8 Since HD affects decision-making capacity in later stages, it is imperative that EOL discussions occur early in the disease course. 9 A working group on EOL planning needs for people with HD funded by the Robert Wood Johnson Foundation recommended health-care providers educate persons with HD on the need to develop and complete ADs. 10 Despite a recognized need, the prevalence of ADs among persons with HD in the United States is not known. People usually have prior knowledge of their HD risk because they have affected family members or have undergone HD genetic testing. Knowledge of gene status for adult onset conditions provides the opportunity to make advance EOL plans. 6 People with HD might be more likely than the general population to have ADs since people with chronic diseases in the general US population are more likely to have ADs than those without chronic disease. 11 The purposes of these analyses were to (1) examine the prevalence of ADs and other EOL plans in a large sample of people at 3 stages of HD and (2) examine the demographic, clinical, and selfreported HRQOL factors associated with having ADs in this sample.
Methods

Setting/Sample
Data for this analysis come from the first phase of the HD Quality of Life (HDQLIFE) study (December 19, 2012 to December 14, 2014) . The purpose of the HDQLIFE study is to develop computer adaptive tests and short forms (SF) to assess patient-reported HRQOL for persons with HD. [12] [13] [14] [15] Participants were individuals with prodromal or manifest HD who were 18 years and older and able to read and understand English. Participants were recruited at a variety of specialized treatment centers across the United States (University of Michigan, University of Iowa, University of California-Los Angeles, Indiana University, Johns Hopkins University, Rutgers University, Struthers Parkinson's Center, Washington University at St Louis, University of California-San Francisco, and the Cleveland Clinic), from the Neurological Predictors of HD (PREDICT-HD) study, 16 the National Research Roster for HD, 17 and articles and advertisements in HD newsletters and websites. This study was approved by all participating institutions' human participants research boards, and all participants provided informed consent.
There were 505 participants in phase 1 of the HDQLIFE study. Data regarding HD stage were missing for 2 participants. Thus, analyses that included comparisons between the HD stage included 503 participants stratified into 3 HD stages: prodromal (n ¼ 197), early (n ¼ 193), and late (n ¼ 113). The prodromal stage included individuals who did not have a clinical diagnosis of HD but had a confirmed CAG repeat !36. Manifest HD participants (n ¼ 308) had a neurologist-confirmed HD clinical diagnosis or received a !99% confidence rating on the motor component of the Unified Huntington Disease Rating Scale (UHDRS), indicating unequivocal signs of HD. Staging of HD for participants with manifest HD was classified according to the UHDRS Total Functional Capacity scale, 18 a clinician-administered scale evaluating day-to-day function regarding occupation, finances, domestic chores, activities of daily living, and care level. Scores range from 0 (low functioning) to 13 (high functioning). Participants were classified as early stage (7) (8) (9) (10) (11) (12) (13) or late stage HD (0-6).
Assessments
Participants completed the HDQLIFE protocol, including questions regarding EOL planning, including ADs, living wills, health-care power of attorney, resuscitation preference, conversations about death and dying, location of death preference, nursing home care, palliative care, and hospice care. All participants were asked to answer questions about all these items. Due to confusion regarding the definitions of these terms in the general public that might be relevant in this study, the focus of our analysis was on comparison of participants with and without ADs. Information regarding ADs was assessed by a single item, "AD (also known as a living will)." Participants were instructed to choose the response that best described where they stood regarding ADs: "I have not thought about getting an advance directive"; "I have thought about getting an advance directive"; "I have taken steps to obtain an advance directive"; and "I have an advance directive." Similar response choices were provided for other items.
Participants also completed newly developed self-report assessments for the presence of HD symptoms, concerns about HD, impact of symptoms, and concerns on HRQOL. We used SF versions of these measures that were created using item response analyses: HDQLIFE Speech Difficulties SF, 15 HDQLIFE Swallowing Difficulties SF, 15 HDQLIFE Chorea SF, 13 HDQLIFE Concern with Death & Dying SF, and HDQLIFE Meaning & Purpose SF. 12 All HDQLIFE measures generate T scores on a T-metric relative to other individuals with HD. T Scores are standardized scores with a mean of 50 and standard deviation of 10; higher scores indicate more of the construct being measured (eg, more speech difficulty, or greater meaning and purpose). Participants also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety SF 19 ; higher scores indicate more anxiety and are scored on a T-metric with the general population as referent.
Trained clinicians administered the UHDRS Total Motor Score in person. Participants completed patient-reported outcome (PRO) measures through PROMIS Assessment Center (https://www.assessmentcenter.net) at a designated computer or tablet during the study visit or were asked to complete it within 2 weeks of the study visit. Participants and those assisting them were instructed that responses were to come directly from participants (ie, assistance was limited to logging into the online study platform, reading questions aloud, and/or clicking response options, when needed).
Data Analysis
Participants were classified as "with ADs" when participants selected the response option "I have an advance directive"; all other responses to that question were classified as "without ADs." We calculated descriptive statistics for demographic variables (age, gender, race, ethnicity, marital status, and years of education), and scores on HDQLIFE and PROMIS measures. Analyses of variance (ANOVAs) were used to compare demographic differences between prodromal, early, and late stages. Sociodemographic and clinical characteristics of participants with and without ADs were compared using w 2 for categorical data: gender, race, marital status, and HD stage; independent t tests were conducted to compare continuous data: age, years of education, and self-report SF (HDQLIFE Chorea, HDQLIFE Speech, HDQLIFE Swallowing, HDQLIFE Concern with Death & Dying, HDQLIFE Meaning & Purpose, and PROMIS Anxiety). We used an a of 0.05 for all t tests. We used Bonferroni-adjusted a levels for the variable groups demographics (0.05/5 variables ¼ 0.01) and HDQLIFE/PRO-MIS measures (0.05/6 variables ¼ 0.008). We did not correct for all variables together (0.05/12 ¼ 0.004) because this is the first known analysis on this topic and we did not want to miss potentially important differences that could be further examined in future studies.
In the logistic regression model, variables that were significantly different (P < .05) between participants with and without ADs in w 2 and t tests were included to determine which factors independently increased odds of having ADs: age, HD stage, education, HDQLIFE Concern for Death & Dying, HDQLIFE Meaning & Purpose, and PROMIS Anxiety. Age and years of education were entered as continuous variables, and T scores were used for HDQLIFE and PROMIS Anxiety. Huntington Disease Quality of Life Swallowing was not included because the difference between those with ADs (53.83) and without ADs (52.78) was unlikely to be clinically meaningful. Although not significant in t tests, HDQLIFE Concern for Death & Dying was included in the model because this psychological variable might impact whether a person has ADs.
Results
Participant demographics are shown in Table 1 . The age range of participants was 18 to 81, mean 49.04 years. Most participants were white (96%) and not Hispanic (93.7%). There were some notable differences in ANOVA comparisons between prodromal versus early and prodromal versus late-stage groups on some variables: there were differences in age, F 2,500 ¼ 44.377, P < .001, and years of education, F 2,498 ¼ 15.415, P < .001, with participants in the prodromal stage being younger and having more years of education than those in the early and those in the late stage. More prodromal stage participants were married compared to early stage, w 2 (2, 502) ¼ 8.12, P ¼ .017.
Overall, 38.2% of participants reported they had ADs. Frequencies and percentages for ADs and associated EOL planning are presented in Table 2 for each HD stage. In general, higher percentages of participants in the late stage had ADs and other EOL plans. w 2 Results (Table 3 ) indicated significant differences between participants with and without ADs for the HD stage, w 2 (2, n ¼ 503) ¼ 9.01. Participants in the late-stage HD were more likely to have ADs than those in prodromal or early stage HD. In t test analyses (Table 3) , there were significant differences between participants with and without AD based on age, t(503) ¼ 8.63, P ¼ <.001; years of education, t(501) ¼ À2.89, P ¼ .004; and HDQLIFE Meaning & Purpose, t(493) ¼ 2.92, P ¼ .004. Participants were more likely to have ADs if they were older, had more years of education, and higher scores on HDQLIFE Meaning and Purpose and HDQLIFE Swallowing, and lower scores on PROMIS Anxiety, although Swallowing and Anxiety were not significant after correcting for multiple comparisons.
The multivariable logistic regression model explained 72.4% of the variance in predicting whether a participant had ADs ( Dying, HDQLIFE Meaning & Purpose, and PROMIS Anxiety were not associated with higher odds of having ADs.
Discussion
Huntington disease is a devastating disease that causes dementia and premature death. People usually have many years to engage in EOL planning since the disease course spans up to 20 years. We report data on the prevalence of ADs among a large sample of people with HD in the United States. Among the 503 participants in this analysis, 38.2% responded they had ADs. This exceeds 31.3% of participants in a study of persons with HD in the Netherlands, 9 and 26.3% of people in the general US population 11 ; however, it is lower than 47.3% of participants over 60 in the United States with 2 or more chronic conditions. 20 Considering the severity of HD and its association with premature mortality, it is surprising only 38.2% of participants had ADs.
Older age has consistently been associated with having ADs in prior studies, as it was in ours. 9, 11, 20 Our sample is relatively young (mean age ¼ 49.04). When age is considered, prevalence of ADs may be higher than among persons of similar ages without HD. For example, in a study examining prevalence of ADs in the general population, 11 18.2% of participants aged 18 to 54 had ADs. In that light, 38.2% of participants in our study with ADs appears relatively high. On the other hand, it is reasonable to assume that people who know they face significant premature morbidity and death would have even higher prevalence of ADs. Self-reported HD symptoms, including the hallmark symptom chorea, were not associated with increased ADs in our study. Having more self-reported swallowing symptoms was associated with having ADs in bivariate analyses, but the difference in symptoms between those with and without ADs was very small and was not significant after correcting for multiple comparisons. There are some previously documented phenomena in HD that might explain why prevalence of ADs was not as high as expected. For example, decreased awareness of disease symptoms can occur in HD 21 and a tendency for persons with HD to normalize symptoms. 22 Although participants in late-stage HD were almost 3 times more likely than participants in the prodromal stage to have ADs, this could be related more to age than the presence of HD symptoms. Our findings suggest that persons with the HD gene mutation are similar to those without HD with regard to EOL planning, despite knowing more about their potential fate. The HDQLIFE study was not designed specifically to examine this issue, however; thus, it is possible that other designs might better reveal the motivations of persons with HD to make EOL plans.
Participants with late-stage HD in our study might have been diagnosed based on family history and HD symptoms and not have had presymptomatic testing, either by choice or because presymptomatic testing was not available before they developed symptoms. People who get tested presymptomatically might be different from people who learn their gene status through clinical diagnosis. In our study, participants in the prodromal stage had more years of education than those in early and late-stage HD, and more years of education slightly increased the odds of having ADs. Higher education level has previously been associated with having EOL plans in both HD and non-HD samples. 9, 11, [23] [24] [25] The relationship between education and having ADs might be mediated by literacy. 23 The use of jargon, including multiple terms referring to ADs, might not clearly describe the intent and usefulness of ADs to patients with lower literacy.
Participants in our study with higher self-reported scores on the PROMIS Anxiety SF were less likely to have ADs in the bivariate analysis, although it was not significant after correcting for multiple comparisons and it was not a predictor of having ADs in the logistic regression model. In our study, HDQLIFE Concern for Death & Dying was not significantly associated with having ADs. Fear of death, anxiety, and concern might, in fact, lead people to avoid EOL planning in an effort to avoid increasing anxiety. 26 Therefore, it would still be important to assess for anxiety, especially disease-and deathrelated anxiety, in future studies. A potential benefit of presymptomatic HD genetic testing is the ability to plan for the future. 27, 28 Participants in the prodromal stage in our study had undergone presymptomatic HD genetic testing, yet had the lowest prevalence of ADs and other EOL plans in our sample. Thus, genetic testing did not appear to strongly impact making EOL planning in the prodromal stage. However, we cannot exclude that many of these participants will make EOL plans while still cognitively able to do so.
Our study has some limitations that might impact generalizability of our findings. Race and ethnicity are limitations because the vast majority of persons with HD in the United States are of European descent and non-Hispanic; prevalence rates are higher in North America, Europe, and Australia compared to Asia. 29 Advance directives, living will, and other EOL terminology such as palliative care were not defined in the HDQLIFE online survey. Given that literacy is an identified barrier to ADs, 23 participants might have responded without having a clear understanding of these terms. Participants were encouraged to answer all questions but were not forced to answer items. We did not include a response option to indicate when participants did not understand a question. In the future, we could consider defining these terms.
Our sample included more participants in prodromal and early stages than late stage. This is understandable, as decreased cognitive ability in later stages of HD could preclude capacity to provide informed consent. Participants in the prodromal stage in our study might not be representative of most people at risk for HD because they had independently undergone presymptomatic HD testing while the uptake of presymptomatic genetic testing for HD is estimated to be under 20%. 30 Many participants were recruited from sites that have HD Centers of Excellence (COE), which are affiliated with the HD Society of America (HDSA). The COE provide specialized care for people with HD, and the HDSA has published materials on ADs available to members. Therefore, our sample might include people more likely to seek and receive information regarding HD. Although prevalence of ADs was lower than expected, our participants might be more likely to have ADs than people who have not undergone genetic testing, do not have access to a COE, or do not participate in HD-related research.
We cannot exclude the possibility that family members answered items on behalf of participants, despite instructions that answers should come directly from participants. The purpose of the HDQLIFE study is to develop an HRQOL measure for people with HD; the examination of factors associated with having ADs was not a primary aim. Therefore, there are several variables associated with having ADs that we did not measure that have been found to be associated with ADs, including knowledge of ADs, literacy, self-efficacy, religiosity, and illness-related fear. 20, 23, 26, [31] [32] [33] Despite the 2004 recommendations of the HD Peer Workgroup, our findings suggest that prevalence of ADs is low in this population. Interventions designed to increase patientprovider discussions of ADs are effective in increasing the development and use of ADs. 34 An important question remains whether health-care providers provide adequate patient education to persons with HD regarding ADs and at an appropriate level of literacy. Having ADs is often not considered an important issue in HD until the disease symptoms have progressed significantly and the patient and family are considering longterm care placement. Unfortunately, this can result in the patient being unable to voice their preferences due to advancing dementia. 35 There is a recognized need for EOL planning for patients with HD to reduce risk of emotional distress from unwanted, aggressive, and costly EOL care. 10, 36 Although we examined factors associated with having ADs among persons with HD, future studies should identify patient and health-care provider barriers to creating ADs in this population. Data from our study could inform development of specific interventions to increase the prevalence of ADs and EOL planning. A promising method involves using vignettes to illustrate disease-specific EOL scenarios to help patients work through their preferences. 37 This could be adapted for use in HD by providing patients with scenarios based on common causes of death in persons with HD. This technique could aid literacy by explaining often misunderstood medical terms and EOL interventions such as cardiopulmonary resuscitation, feeding tubes, and ventilators. 38 Medicare reimbursement for EOL discussions is a positive step, although these discussions should begin long before patients with HD become Medicare eligible. Prevalence of ADs and EOL plans is surprisingly low considering the severity and long disease course of HD. Health-care providers should actively educate and assist patients with HD in making ADs and EOL plans to specify treatment preferences while they still have the cognitive ability.
